These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11840902)

  • 1. Access to new medications to treat schizophrenia.
    Mark TL; Dirani R; Slade E; Russo PA
    J Behav Health Serv Res; 2002 Feb; 29(1):15-29. PubMed ID: 11840902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States.
    Daumit GL; Crum RM; Guallar E; Powe NR; Primm AB; Steinwachs DM; Ford DE
    Arch Gen Psychiatry; 2003 Feb; 60(2):121-8. PubMed ID: 12578429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
    Opolka JL; Rascati KL; Brown CM; Barner JC; Johnsrud MT; Gibson PJ
    J Clin Psychiatry; 2003 Jun; 64(6):635-9. PubMed ID: 12823076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
    Opolka JL; Rascati KL; Brown CM; Gibson PJ
    Psychiatr Serv; 2004 Feb; 55(2):151-6. PubMed ID: 14762239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia.
    Brown JD; Barrett A; Caffery E; Hourihan K; Ireys HT
    Psychiatr Serv; 2014 Jan; 65(1):121-4. PubMed ID: 24382765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic and clinical variation in clozapine use in the United States.
    Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
    Psychiatr Serv; 2014 Feb; 65(2):186-92. PubMed ID: 24233347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients.
    Herbeck DM; West JC; Ruditis I; Duffy FF; Fitek DJ; Bell CC; Snowden LR
    Psychiatr Serv; 2004 Jun; 55(6):677-84. PubMed ID: 15175466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
    Leslie DL; Rosenheck R
    J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical decision making in antipsychotic drug choice for schizophrenia.
    Hamann J; Langer B; Leucht S; Busch R; Kissling W
    Am J Psychiatry; 2004 Jul; 161(7):1301-4. PubMed ID: 15229068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs.
    Rosenheck R; Leslie D; Sernyak M
    Med Care; 2001 Mar; 39(3):302-8. PubMed ID: 11242324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
    Leslie DL; Rosenheck RA
    Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial disparity in the pharmacological management of schizophrenia.
    Kreyenbuhl J; Zito JM; Buchanan RW; Soeken KL; Lehman AF
    Schizophr Bull; 2003; 29(2):183-93. PubMed ID: 14552495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
    J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.
    Covell NH; Jackson CT; Evans AC; Essock SM
    Schizophr Bull; 2002; 28(1):17-29. PubMed ID: 12047017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.
    Kuno E; Rothbard AB
    Am J Psychiatry; 2002 Apr; 159(4):567-72. PubMed ID: 11925294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Bindman J; Leese M; Schene A; Becker T; Angermeyer MC; Koeter M; Gray R; Tansella M
    Int Clin Psychopharmacol; 2006 Mar; 21(2):73-9. PubMed ID: 16421457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
    McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
    J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia.
    Luo RD; Belleti DA; Tran D; Arcona S; Salen PN
    Int J Psychiatry Med; 2002; 32(3):261-9. PubMed ID: 12489701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.